Drug intelligence / Profile preview

Pep-3

Development stage
Preclinical
Lead developer
Chungang University
Modality
Peptides
Administration
Oral
01

Overview

Pep-3 is a synthetic homo-dimer peptide derived from the hexapeptide FCIGRL-NH2 (Pep-1), which is a fragment of the *Vibrio cholerae* Zonula occludens toxin (ZOT). Developed through a collaboration between Chung-Ang University and the University of Maryland, Pep-3 acts as a tight junction modulator designed to enhance the oral delivery of drugs with poor membrane permeability. It functions by interacting with the zonulin receptor on the intestinal epithelium, triggering a signaling cascade that leads to the reversible opening of intercellular tight junctions. This mechanism increases paracellular permeability, thereby significantly enhancing the oral absorption and bioavailability of therapeutic agents such as Cyclosporin A and Doxorubicin. Pep-3 is primarily investigated as a pharmaceutical excipient or absorption enhancer for oral drug delivery systems.

Other names
ZOT-derived peptide dimerPep-3 peptidePep3 peptidePep 3 peptideFCIGRL-NH2 dimerFCIGRL-NH-2 dimerFCIGRL-NH 2 dimer
02

Targets

PAR2 (Protease-activated receptor 2)

Beyond the preview

Go deeper on Pep-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pep-3.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call